Among this quarter's new drugs are the first monoclonal antibody (mAb) therapies against programmed cell death inhibitor 1 (PD1), the first phosphoinositide 3-kinase (PI3k) inhibitor, an orexin inhibitor for insomnia and the first pan-histone deacetylase (HDAC) inhibitor approved in 5 years. Six drugs received breakthrough drug designations, with a rash of anti-fibrotic drugs. The first bona fide biosimilar application goes up for review by the US Food and Drug Administration (FDA) in the next quarter.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DeFrancesco, L. Drug pipeline 3Q14. Nat Biotechnol 32, 1080 (2014). https://doi.org/10.1038/nbt.3072
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3072
